Work

483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(21)00641-4

Authors: T.S.K. Mok, R.M. Jotte, F. Cappuzzo, M. Reck, V. Papadimitrakopoulou, H.J. West, A. Sandler, S. Mocci, S. Coleman, T. Asakawa, M.A. Socinski

Institutions: Chinese University of Hong Kong, Rocky Mountain Cancer Centers, Ospedale di Livorno, German Center for Lung Research, LungenClinic Grosshansdorf, The University of Texas MD Anderson Cancer Center, Swedish Medical Center, Genentech, Florida Hospital Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2587326702

FWCI:

Cites:

Cited by:

Related to: 10